Becton Dickinson and Co (BDX) Stake Lowered by ProVise Management Group LLC

Share on StockTwits

ProVise Management Group LLC reduced its holdings in Becton Dickinson and Co (NYSE:BDX) by 31.1% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,561 shares of the medical instruments supplier’s stock after selling 706 shares during the quarter. ProVise Management Group LLC’s holdings in Becton Dickinson and were worth $374,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Ascension Asset Management LLC increased its stake in Becton Dickinson and by 4.2% in the 2nd quarter. Ascension Asset Management LLC now owns 4,970 shares of the medical instruments supplier’s stock valued at $1,191,000 after purchasing an additional 200 shares in the last quarter. Bfsg LLC increased its stake in Becton Dickinson and by 1.9% in the 2nd quarter. Bfsg LLC now owns 10,515 shares of the medical instruments supplier’s stock valued at $2,519,000 after purchasing an additional 201 shares in the last quarter. Toth Financial Advisory Corp increased its stake in Becton Dickinson and by 0.8% in the 2nd quarter. Toth Financial Advisory Corp now owns 24,989 shares of the medical instruments supplier’s stock valued at $5,986,000 after purchasing an additional 203 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its stake in Becton Dickinson and by 0.4% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 50,849 shares of the medical instruments supplier’s stock valued at $12,181,000 after purchasing an additional 204 shares in the last quarter. Finally, Chesapeake Wealth Management increased its stake in Becton Dickinson and by 5.5% in the 2nd quarter. Chesapeake Wealth Management now owns 4,179 shares of the medical instruments supplier’s stock valued at $1,001,000 after purchasing an additional 219 shares in the last quarter. 86.73% of the stock is owned by institutional investors and hedge funds.

Several equities analysts recently weighed in on the company. ValuEngine raised Becton Dickinson and from a “hold” rating to a “buy” rating in a research note on Tuesday, June 26th. Wells Fargo & Co reissued an “outperform” rating and set a $290.00 price target (up previously from $275.00) on shares of Becton Dickinson and in a research report on Thursday. They noted that the move was a valuation call. Citigroup raised their price target on Becton Dickinson and from $274.00 to $283.00 and gave the stock a “buy” rating in a research report on Wednesday, August 8th. JPMorgan Chase & Co. raised Becton Dickinson and from a “neutral” rating to an “overweight” rating and set a $175.00 price target for the company in a research report on Thursday, June 21st. Finally, Royal Bank of Canada reissued a “hold” rating and set a $248.00 price target on shares of Becton Dickinson and in a research report on Friday, August 3rd. Four equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $251.64.

Becton Dickinson and stock opened at $255.66 on Friday. The company has a quick ratio of 0.81, a current ratio of 1.23 and a debt-to-equity ratio of 0.95. The firm has a market cap of $68.92 billion, a price-to-earnings ratio of 26.97, a P/E/G ratio of 1.76 and a beta of 1.10. Becton Dickinson and Co has a fifty-two week low of $191.53 and a fifty-two week high of $263.37.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings results on Thursday, August 2nd. The medical instruments supplier reported $2.91 earnings per share for the quarter, topping the consensus estimate of $2.86 by $0.05. The company had revenue of $4.28 billion during the quarter, compared to the consensus estimate of $4.25 billion. Becton Dickinson and had a return on equity of 14.16% and a net margin of 4.73%. Becton Dickinson and’s revenue was up 41.0% compared to the same quarter last year. During the same quarter last year, the business posted $2.46 earnings per share. research analysts anticipate that Becton Dickinson and Co will post 11.01 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 28th. Stockholders of record on Friday, September 7th will be given a $0.75 dividend. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.17%. The ex-dividend date is Thursday, September 6th. Becton Dickinson and’s dividend payout ratio is currently 31.65%.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

Featured Article: Hedge Funds – How They Work For Investors

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply